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A randomized placebo-controlled trial of alphacalcidol on the preservation of beta cell 
function in children with recent onset type 1 diabetes 
ABSTRACT 
Background & aims: This participant-blinded parallel-group randomized placebo-controlled 
study demonstrated that alfacalcidol (vitamin D analogue) preserves beta cell function in 
newly diagnosed type 1 diabetes (T1DM) in children. Methods: Subjects from outpatient 
clinic were randomized to intervention and control groups. Inclusion: (1) age 8–15, (2) 
T1DM, (3) duration <8 weeks, (4) no chronic diseases, (5) stable diet. Exclusion: (1) vitamin 
D, calcium supplements or fortified foods, (2) hypercalcemia. Intervention group received 
alfacalcidol 0.25 μg twice daily, while control group received placebo. Insulin given 
physician-titrated to blood glucose. Safety monitored by serum calcium and phosphate. Beta 
cell function assessed at 0, 3, 6 months using fasting C-peptide (FCP) and daily insulin 
dosage per body weight (DID). Primary outcome measured using multivariate repeated 
measures GLM-ANOVA, with FCP and DID as primary measures and age, gender, sunlight 
exposure, 25-hydroxy vitamin D, and HbA1c as covariates. Results: Of 61 subjects, 7 
dropped out. GLM-ANOVA showed that groups were different (p = 0.019, Eta-squared = 
0.087), with no significant covariates. FCP was higher and DID lower in the intervention 
group, with males having stronger responses to alfacalcidol (p = 0.001). No adverse effects 
were observed. Conclusions: The study confirmed that alfacalcidol can safely preserve beta 
cell function in newly diagnosed T1DM in children, with a stronger effect in males. 
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